Overview
This is an ambispective, single-center study to evaluate the survival outcomes, adverse events and predictive biomarkers for CDK4/6 inhibitors in patients with hormone receptor-positive advanced breast cancer.
Eligibility
Inclusion Criteria:
- Aged ≥18 and older
- Confirmed diagnosis of hormone receptor-positive breast cancer.
- Subjects with locoregionally recurrent or metastatic disease not amenable to curative therapy.
- Subjects have received or plan to receive CDK4/6 inhibitors for advanced disease.
- ECOG 0-2
- Adequate organ function
Exclusion Criteria:
- Subjects disable to swallow pills.
- History of immunodeficiency disease